<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02337842</url>
  </required_header>
  <id_info>
    <org_study_id>12-0033</org_study_id>
    <secondary_id>HHSN272200800006C</secondary_id>
    <nct_id>NCT02337842</nct_id>
  </id_info>
  <brief_title>Phase I Study to Determine the Optimal Human Challenge Dose for a Norovirus GII.4 Challenge Stock (CIN-1)</brief_title>
  <official_title>Phase I Study to Determine the Optimal Human Challenge Dose for a Norovirus GII.4 Challenge Stock (CIN-1)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Institute of Allergy and Infectious Diseases (NIAID)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Institute of Allergy and Infectious Diseases (NIAID)</source>
  <brief_summary>
    <textblock>
      This is phase I, double blind, placebo-controlled safety and infectivity study of&#xD;
      experimental human Norovirus genogroup GII.4 administered to healthy adults 18-49 years of&#xD;
      age. Subjects susceptible to the human norovirus GII.4 challenge strain. The challenge study&#xD;
      will be conducted in 2-3 cohorts of approximately 20 subjects each.Subjects will remain in&#xD;
      the inpatient facility for at least four days following challenge and assessed daily for&#xD;
      clinical and virologic evidence of norovirus infection. The primary objectives are to&#xD;
      evaluate the safety and reactogenicity of the norovirus GII.4 (CIN-1; 031693) challenge stock&#xD;
      and to determine a safe and optimal challenge dose of Norovirus GII.4 Challenge Stock&#xD;
      norovirus to achieve illness in &gt; /=50% of subjects. Illness is defined as: diarrhea (&gt;3&#xD;
      loose or liquid stools or &gt;300 gm of loose or liquid stool /24h), and/or vomiting during the&#xD;
      inpatient period, in a participant with evidence of infection.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is phase I, double blind, placebo-controlled safety and infectivity study of&#xD;
      experimental human Norovirus genogroup GII.4 administered to healthy adults 18-49 years of&#xD;
      age. The unblinded pharmacist will assign treatments. Subjects will be admitted to an&#xD;
      inpatient nursing unit, challenged with live GII.4 Norovirus strain by oral administration,&#xD;
      remain in the unit for at least 4 days following challenge and then followed for&#xD;
      post-challenge safety and efficacy with multiple clinical assessments and collection of blood&#xD;
      and stool specimens.&#xD;
&#xD;
      Subjects susceptible to the human norovirus GII.4 challenge strain, CIN-1 (i.e. presence of a&#xD;
      functional FUT-2 gene), regardless of ABO blood type, will be housed in the Cincinnati Center&#xD;
      for Clinical Research (CCCR) inpatient facility and challenged orally with different doses of&#xD;
      the virus. The challenge study will be conducted in 2-3 cohorts of approximately 20 subjects&#xD;
      each, with the initial cohort receiving 103 RT-PCR units or placebo (9 &quot;challenge&quot; and 1&#xD;
      &quot;placebo&quot; per 10 subjects). Based on the illness rate of acute gastroenteritis (AGE) in the&#xD;
      initial cohort, the second cohort will be enrolled to receive a challenge dose based on the&#xD;
      results of the previous studies. Additional cohorts may be necessary. Illness is defined as&#xD;
      infection accompanied by vomiting and/or diarrhea during the inpatient stay.Two to three&#xD;
      additional subjects per cohort will serve as alternates in the event that any of the study&#xD;
      subjects are unavailable or become ineligible at the time of the inpatient study.Subjects&#xD;
      will remain in the inpatient facility for at least four days following challenge and assessed&#xD;
      daily for clinical and virologic evidence of norovirus infection. Subjects will return to the&#xD;
      investigational site for evaluation on Day 6 (6-8 days) and about 15 (14-16 days) and 30 days&#xD;
      (28-35 days), and 45 (40-45 days), and (55-65) post challenge.&#xD;
&#xD;
      The primary objectives are to evaluate the safety and reactogenicity of the norovirus GII.4&#xD;
      (CIN-1; 031693) challenge stock and to determine a safe and optimal challenge dose of&#xD;
      Norovirus GII.4 Challenge Stock norovirus to achieve illness in &gt; /=50% of subjects. Illness&#xD;
      is defined as: diarrhea (&gt;3 loose or liquid stools or &gt;300 gm of loose or liquid stool /24h),&#xD;
      and/or vomiting during the inpatient period, in a participant with evidence of infection. The&#xD;
      secondary objectives are to determine the rate of infection in study participants by; virus&#xD;
      detection in stool by Norovirus GII.4 Challenge Stock-specific qRT-PCR and anti- Norovirus&#xD;
      GII.4 Challenge Stock serum IgG by ELISA (&gt; /=4 fold rise from baseline to Day 30), determine&#xD;
      the quantity and duration of virus shedding in stool by qRT-PCR, conduct Time-to-event&#xD;
      analysis to estimate the median time to cessation of shedding using Kaplan-Meier methods,&#xD;
      determine the modified Vesikari score as a measure of gastroenteritis severity, determine&#xD;
      Norovirus GII.4 Challenge Stock-specific immunoglobulin titers by ELISA before and after the&#xD;
      challenge; Serum IgA and IgG, Serum Blockade IgG, Salivary IgA, determine the effect of&#xD;
      preexisting Norovirus GII.4 Challenge Stock-specific Immunoglobulin in serum and saliva on&#xD;
      the rate of infection, determine total and Norovirus GII.4 Challenge Stock-specific IgA- and&#xD;
      IgG-Secreting Cells in circulation by ELISpot assay.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Withdrawn</overall_status>
  <start_date>September 2015</start_date>
  <completion_date type="Actual">January 2016</completion_date>
  <primary_completion_date type="Actual">January 2016</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of subjects experiencing any mild, moderate or severe reactogenicity outcomes.</measure>
    <time_frame>Day 1 to Day 180</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Proportion of subjects with Norovirus-GII.4 Challenge Stock (CIN-1; 031693) associated illness following norovirus GII.4 challenge</measure>
    <time_frame>Day 1 to Day 5</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of serious adverse events related to virus challenge reported at any point during the study</measure>
    <time_frame>Day 1 to Day 180</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of subjects experiencing Grade 3 adverse events after virus challenge throughout the study to day 30</measure>
    <time_frame>Day 1 to Day 30</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Determine Infectious Dose50 based on infection rate after challenge with various doses.</measure>
    <time_frame>Day 1 to Day 180</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Infection rate within each dose, defined as proportion of subjects excreting challenge virus in stool 24 hours after challenge</measure>
    <time_frame>24 hours after challenge</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of subjects with norovirus specific IgG-ASC / 10^6 PBMC (freshly isolated PBMCs)</measure>
    <time_frame>Day 1 to Day 45</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical Severity Score of vomiting and/or diarrhea related to the challenge strain using the Modified Vesikari Scale</measure>
    <time_frame>Day 1 to Day 5</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>95% confidence intervals of vomiting and/or diarrhea related to the challenge strain</measure>
    <time_frame>Day 1 to Day 5</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean duration (hours) of vomiting and/or diarrhea related to the challenge strain</measure>
    <time_frame>Day 1 to Day 5</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>At any time after challenge Proportion of subjects with &gt;/= 4 fold rise from the baseline in virus-specific antibody titers in serum(IgA, IgG Blockade), or salivary IgA</measure>
    <time_frame>Day 1 to Day 45</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Infection rate within each dose defined as proportion of subjects showing a &gt; /=4 fold rise in virus specific serum IgG from baseline to Day 30</measure>
    <time_frame>Day 1 to Day 30</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of subjects with norovirus specific IgA- ASC / 10^6 PBMC (freshly isolated PBMCs)</measure>
    <time_frame>Day 1 to Day 45</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Correlation of challenge outcome (infection) and preexisting serum immunoglobulins.</measure>
    <time_frame>Day 1 to Day 45</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time-to-cessation of virus shedding in stool in hours for each challenge dose.</measure>
    <time_frame>Day 1 to Day 60</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Magnitude and duration of virus shedding in stool reported as qRT-PCR units for each challenge dose</measure>
    <time_frame>Day 1 to Day 60</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">0</enrollment>
  <condition>Gastroenteritis Norovirus</condition>
  <arm_group>
    <arm_group_label>Cohort 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>N= 9 subjects will receive single oral dose of GII.4 CIN-1 at 10^3 RT-PCR units and N=1 single oral dose Placebo.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>N=9 subjects will receive single oral dose of GII.4 CIN-1 either at 10^2 or 5x10^3 RT-PCR units and N=1 single oral dose of Placebo.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 4</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>N=36 subjects will receive single oral dose of GII.4 CIN-1 at either 5x10^4 or 5x10^3 or 10^3 or 10^2 or 10^4 or 5x10^2 or 5x10^1RT-PCR units , N=4 subjects receive a single oral dose of Placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>N=18 subjects will receive single oral dose of GII.4 CIN-1 at either 10^4, 10^3, 5x10^2 or 5x10^1 RT-PCR units and N=2 single oral dose of Placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Norovirus GII.4 Challenge Pool CIN-1</intervention_name>
    <description>Norovirus Challenge GII.4 Strain 031693. Cohort 1: receive single oral dose of GII.4 CIN-1 at 10^3 RT-PCR units. Cohort 2: single oral dose of GII.4 CIN-1 either at 10^2 or 5x10^3 RT-PCR units. Cohort 3: single oral dose of GII.4 CIN-1 at either 10^4, 10^3, 5x10^2 or 5x10^1 RT-PCR units. Cohort 4: single oral dose of GII.4 CIN-1 at either 5x10^4 or 5x10^3 or 10^3 or 10^2 or 10^4 or 5x10^2 or 5x10^1RT-PCR units.</description>
    <arm_group_label>Cohort 1</arm_group_label>
    <arm_group_label>Cohort 2</arm_group_label>
    <arm_group_label>Cohort 3</arm_group_label>
    <arm_group_label>Cohort 4</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo: 80 ml of sterile water for oral administration</description>
    <arm_group_label>Cohort 1</arm_group_label>
    <arm_group_label>Cohort 2</arm_group_label>
    <arm_group_label>Cohort 3</arm_group_label>
    <arm_group_label>Cohort 4</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        Subjects must meet all of the following inclusion criteria:&#xD;
&#xD;
          -  Subject able to provide written informed consent.&#xD;
&#xD;
          -  Male or non-pregnant females between the ages of 18 and 49 years, inclusive.&#xD;
&#xD;
          -  Women of childbearing potential must be practicing abstinence or using an acceptable&#xD;
             method of birth control for at least 30 days prior to enrollment through day 45 after&#xD;
             receipt of the challenge virus. Male subjects must agree not to father a child prior&#xD;
             to day 45 after receipt of the challenge virus.&#xD;
&#xD;
               -  A woman is considered of childbearing potential unless post-menopausal (absence&#xD;
                  of menses for &gt;/= 1 year) or surgically sterilized (tubal ligation, bilateral&#xD;
                  oophorectomy or hysterectomy).&#xD;
&#xD;
               -  Acceptable contraception methods for women include but are not limited to: sexual&#xD;
                  abstinence from intercourse with men, monogamous relationship with vasectomized&#xD;
                  partner who has been vasectomized for 6 months or more prior to the subject&#xD;
                  enrolling in the study, barrier methods such as condoms or diaphragms with&#xD;
                  spermicide or foam, effective devices (IUDs, NuvaRingÂ®) or licensed hormonal&#xD;
                  products such as implants, injectables or oral contraceptives.&#xD;
&#xD;
          -  For women of childbearing potential, must have a negative serum or urine pregnancy&#xD;
             test at screening and negative urine or serum pregnancy test within 24 hours prior to&#xD;
             challenge.&#xD;
&#xD;
          -  Are in good general health, as determined by the study investigator within 60 days of&#xD;
             challenge.&#xD;
&#xD;
          -  Demonstrate knowledge and comprehension of the study by scoring &gt;/=70 procent on a&#xD;
             quiz of the study protocol and policies.&#xD;
&#xD;
          -  Willing and able to participate in all study visits, including an inpatient stay of at&#xD;
             least 96 hours.&#xD;
&#xD;
          -  Demonstrated to be secretor positive for HBGA binding.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        Subjects who meet any of the following exclusion criteria will be excluded from study&#xD;
        participation:&#xD;
&#xD;
          -  Have household contact with or have daily contact with children less than 2 years of&#xD;
             age or persons older than 70 years of age.&#xD;
&#xD;
          -  Have expected occupational or social contact with immunocompromised individuals in the&#xD;
             8 weeks after challenge, including persons with HIV infection or active cancer,&#xD;
             children &lt; 2 years of age, pregnant women or persons who are immunosuppressed (e.g.&#xD;
             history of stem cell or organ transplantation) and/or provide any child day care&#xD;
             services (in-home or non-residential facility).&#xD;
&#xD;
          -  Are healthcare workers with patient contact in the 8 weeks after challenge.&#xD;
&#xD;
          -  Are food service workers expected to prepare/handle food in the 8 weeks after&#xD;
             challenge.&#xD;
&#xD;
          -  Plan to be living in a confined environment (e.g. ship, camp, or dormitory) within 8&#xD;
             weeks after receiving the challenge strain.&#xD;
&#xD;
          -  For females, are pregnant or plan to become pregnant at any time between the Screening&#xD;
             Visit through 45 days after receipt of the challenge virus.&#xD;
&#xD;
          -  Are breastfeeding or plan to breastfeed at any given time throughout the study.&#xD;
&#xD;
          -  Have a history of gastroenteritis in the 4 weeks prior to challenge or any history of&#xD;
             chronic or recurrent diarrhea or vomiting.&#xD;
&#xD;
          -  Have a history of malabsorption or maldigestion disorder (e.g. celiac sprue), major&#xD;
             gastrointestinal (GI) surgery, irritable bowel syndrome or any other chronic GI&#xD;
             disorders that would interfere with the study, including chronic constipation or&#xD;
             increased stool frequency.&#xD;
&#xD;
          -  Have moderate or severe illness and/or an oral temperature &gt;/=100.4 degre Fahrenheit&#xD;
             and/or diarrhea or vomiting within seven days prior to challenge.&#xD;
&#xD;
          -  Have a pulse rate less than 55 bpm or greater than 100 bpm. If heart rate is &lt;55 beats&#xD;
             per minute and the investigator determines that this is not clinically significant&#xD;
             (e.g., athletes) and heart rate increases &gt; 55 beats per minute on moderate exercise&#xD;
             (two flights of stairs), subject will not be excluded.&#xD;
&#xD;
          -  Have a systolic blood pressure less than 90 mm Hg or greater than 140 mm Hg on two&#xD;
             separate measurements (screening and pre-challenge).&#xD;
&#xD;
          -  Have a diastolic blood pressure less than 50 mm Hg or greater than 90 mmHg on two&#xD;
             separate measurements (screening and pre-challenge).&#xD;
&#xD;
          -  Have long-term use (&gt;/=2 weeks) of high-dose oral (&gt;/= 20 mg per day prednisone or&#xD;
             equivalent) or parenteral glucocorticoids, or high-dose inhaled steroids for greater&#xD;
             than 7 days in the last 6 months.&#xD;
&#xD;
          -  Have an autoimmune, inflammatory, vasculitic or rheumatic disease, including but not&#xD;
             limited to systemic lupus erythematosus, polymyalgia rheumatic, rheumatoid arthritis&#xD;
             or scleroderma.&#xD;
&#xD;
          -  Have HIV, Hepatitis B, Hepatitis C infection or untreated latent syphilis.&#xD;
&#xD;
          -  Have a seizure disorder.&#xD;
&#xD;
          -  Have an active malignancy or history of malignancy (excluding nonmelanotic skin cancer&#xD;
             in remission without treatment for more than 5 years) or current use of&#xD;
             immunosuppressive or cytotoxic therapy.&#xD;
&#xD;
          -  Have positive fecal culture for E. coli O157:H7, Salmonella, Campylobacter, Yersinia,&#xD;
             or Shigella, evidence of norovirus in the stool by RT-qPCR or pathogenic ova and&#xD;
             parasites detected on microscopic examination at screening.&#xD;
&#xD;
          -  Have abnormal screening laboratory test results per laboratory reported normal values&#xD;
             and Section 18 Appendix B for white blood cells (WBCs), hemoglobin (Hgb), platelets,&#xD;
             absolute neutrophil count (ANC), bilirubin, potassium, sodium, Hemoglobin A1-c&#xD;
             (HgbA1-c) and urine protein.&#xD;
&#xD;
          -  Serum creatinine greater than 1.1 x ULN&#xD;
&#xD;
          -  Alanine aminotransferase (ALT), greater than 1.1 x ULN.&#xD;
&#xD;
          -  Have a chronic condition that the study physician feels would pose a threat to&#xD;
             participating subjects, including, but not limited to solid organ or stem cell&#xD;
             transplantation, diabetes, clinically significant history of immunosuppressive&#xD;
             illness, gall bladder disease, heart disease, lung disease, pancreatic disease, renal&#xD;
             disease or neurological disease.&#xD;
&#xD;
          -  Have abnormal findings on screening electrocardiogram deemed clinically significant by&#xD;
             study physician.&#xD;
&#xD;
          -  Have ongoing drug abuse/dependence (including alcohol), or a history of these issues&#xD;
             within 5 years of enrollment.&#xD;
&#xD;
          -  Have a positive urine test for opiates.&#xD;
&#xD;
          -  Have any medical, psychiatric, occupational, or behavioral problems that make it&#xD;
             unlikely for the subject to comply with the protocol as determined by the&#xD;
             investigator.&#xD;
&#xD;
          -  Are unwilling to comply with study procedures including abstaining from smoking for&#xD;
             the duration of the inpatient portion of the study.&#xD;
&#xD;
          -  Have participated in a previous NoV challenge study or NoV vaccine study.&#xD;
&#xD;
          -  Have received experimental products within 30 days before study entry or plan to&#xD;
             receive experimental products at any time during the study.&#xD;
&#xD;
          -  Plans to enroll in another clinical trial that could interfere with safety assessment&#xD;
             of the investigational product at any time during the study period, including study&#xD;
             interventions such as drugs, biologics or devices.&#xD;
&#xD;
          -  Plan to donate blood during the course of the study.&#xD;
&#xD;
          -  Have received a live vaccine within 30 days before study entry or plan to receive a&#xD;
             live vaccine prior to Day 30 of the study.&#xD;
&#xD;
          -  Have received an inactivated vaccine within 14 days before study entry or plan to&#xD;
             receive an inactivated vaccine prior to Day 14 of the study.&#xD;
&#xD;
          -  Have received parenteral immunoglobulin or blood products within 3 months of the study&#xD;
             start, or plan to receive parenteral immunoglobulin or blood products within 3 months&#xD;
             after receiving the study agent.&#xD;
&#xD;
          -  Use of antibiotics within 7 days prior to entry into the inpatient facility.&#xD;
&#xD;
          -  Use of any H2 receptor antagonists (e.g., Tagamet, Zantac, and Pepcid), proton pump&#xD;
             inhibitors (e.g., Prilosec, OTC, Protonix, and Prevacid), or prescription acid&#xD;
             suppression medication or over-the-counter (OTC) antacids in the 72 hours prior to NoV&#xD;
             challenge.&#xD;
&#xD;
          -  Use of prescription and OTC medications containing acetaminophen, aspirin, ibuprofen,&#xD;
             and other non-steroidal anti-inflammatory drugs within 48 hours prior to NoV&#xD;
             challenge.&#xD;
&#xD;
          -  Regular use of laxatives or anti-motility agents.&#xD;
&#xD;
          -  Have a history of allergy to sodium bicarbonate.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>49 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Cincinnati Children's Hospital Medical Center - Infectious Diseases</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45229-3026</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2015</verification_date>
  <study_first_submitted>January 8, 2015</study_first_submitted>
  <study_first_submitted_qc>January 8, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 14, 2015</study_first_posted>
  <last_update_submitted>June 2, 2016</last_update_submitted>
  <last_update_submitted_qc>June 2, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 3, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>NoV, CIN-1, GII4. Norovirus, challenge, FUT-2 gene, HBGA-blocking Ab</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gastroenteritis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

